Treat and Reduce Obesity Act of 2025

The Treat and Reduce Obesity Act of 2025 (S.1973) was introduced on June 5, 2025 by Senator Bill Cassidy (R-LA) with 22 bipartisan cosponsors. The bill has been referred to the Senate Committee on Finance — the first step in the legislative process. A companion bill (HR4231) was introduced in the House and referred to Energy and Commerce and Ways & Means committees. This is early-stage legislation with a long path to passage. The money trail is critical: this bill does NOT appropriate any funds. It amends the Social Security Act (Title XVIII) to expand Medicare Part D coverage to include obesity drugs and intensive behavioral therapy. The mechanism is regulatory expansion of the existing Medicare benefit, not a new spending authorization. If enacted, CMS must update its formulary and coverage rules — the spending impact would flow through existing Part D premium/taxpayer funding mechanisms, estimated by bill findings at over $50 billion annually in obesity-related Medicare costs. The structural winners are pure-play GLP-1 manufacturers $LLY (tirzepatide) and $NVO (semaglutide). The bill creates a new government-subsidized patient pool of ~27 million Medicare beneficiaries aged 60+ with obesity, per CDC data cited in the bill. This is a direct market expansion for weight-loss drugs previously excluded from Medicare. The bill also expands intensive behavioral therapy providers beyond primary care physicians to include PAs, NPs, and specialists — broadening the referral base for drug prescriptions. Real market data as of April 28, 2026 shows $NVO at $41.17 with a 14.23% 30-day gain, while $LLY trades at $874, down 0.48% over 30 days but down 5.15% in the past week. $LLY's stock has declined from $905+ levels in mid-April to $868-$874 range, potentially creating a more attractive entry point if investors view the bill's progress as likely. $NVO's 30-day outperformance suggests the market is pricing in disproportionate expectations for Novo's Medicare exposure, though both companies face similar addressable market expansion. The timeline is long: the bill must pass the Finance Committee, Senate floor, House passage (likely through companion HR4231), and Presidential signature. The 119th Congress runs through January 2027, giving ~8 months remaining. The April 18, 2026 Executive Order on accelerating medical treatments for serious mental illness is not directly relevant to obesity drug coverage — there is no amplification or conflict between the two actions.